Top Chemicals - Others Stocks India (Week of May 10, 2026)

Sector Pulse

The 'Chemicals - Others' sub-sector is currently navigating a highly constrained operating environment, characterized by severe margin compression and mixed demand signals. Across the 3 constituents analyzed, profitability has taken a material hit. PCCL saw its operating profit plummet by 89% year-on-year, while CAMLINFINE and SHK both reported margin contraction due to raw material inventory lags, fixed cost under-absorption, and front-ended operating expenses. The demand environment remains MIXED, with 3 of 3 constituents citing headwinds ranging from European geopolitical softness to intense local competition in India.

Catalysts Playing Out Across the Pack

Despite the near-term gloom, managements are pointing to specific structural unlocks. The primary driver is Regulatory Approval Or License Win. CAMLINFINE is actively holding back 400 tons of Vanillin inventory to capitalize on a US import tariff reduction from 50% to 25%, which is expected to boost realizations to $14-14.5/kg. Meanwhile, PCCL's entire growth trajectory hinges on an NGT appeal to overturn a CAQM ban on capacity augmentation. Additionally, Operating Leverage Inflection is a shared theme; CAMLINFINE expects production costs to drop to $8/kg as Vanillin volumes scale to 4,000 tons, and SHK is targeting a 400 bps margin expansion to 17% as new factories come online.

What Managements Are Guiding

Forward guidance reflects a dichotomy between near-term pain and long-term optimism. SHK lowered its short-term EBITDA margin guidance from 15% to 13% due to high insurance costs and growth-led investments, but reaffirmed its 12% revenue CAGR target. CAMLINFINE met its revised ₹2,000-2,100 Cr FY26 revenue guidance and raised its FY27 outlook to ₹2,200 Cr. Capex remains a priority, with SHK committing ₹110-120 crore over the next 12-18 months and CAMLINFINE guiding for ₹40-50 crore, indicating that managements are looking past current cyclical troughs.

Sub-Sector Aggregates

The quantitative aggregates underscore the sector's current profitability crisis. The EBITDA Margin Range sits at a depressed 4.89% to 13.0%, with 2 of 3 constituents (PCCL and CAMLINFINE) reporting margins below 10%. This compression is largely driven by the inability to pass on costs swiftly and the burden of older, expensive raw material inventory. Despite these compressed margins, Capex Commitments range from ₹40 Cr to ₹120 Cr, showing that balance sheets are being stretched to fund future growth and geographical expansion.

Shared Risks (9-type taxonomy)

The sector is heavily exposed to commodity and regulatory risks. All 3 constituents flagged commodity-related pressures: CAMLINFINE faces falling global prices for core antioxidants, SHK is battling a time lag in passing through lower raw material costs, and PCCL is constrained by a national import ceiling on Raw Petroleum Coke. Regulatory risks are equally severe, with PCCL's expansion halted by environmental boards and CAMLINFINE's realizations dependent on the final signing of the US-India trade treaty. Furthermore, litigation risk materialized sharply for CAMLINFINE via a massive fire in Brazil, resulting in a ₹33 Cr book value loss.

Bottom Line

The sector is currently in a transition phase, absorbing high raw material costs and regulatory hurdles while investing heavily in future capacity. While the near-term margin profile is weak, the active playout of regulatory tariff cuts and impending operating leverage provide a clear line of sight to profitability recovery in FY27.